Page last updated: 2024-12-07
gossypol beta-aminoethyl sodium sulfate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
gossypol beta-aminoethyl sodium sulfate: don't confuse with MEGACINS [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 166485 |
MeSH ID | M0087371 |
Synonyms (6)
Synonym |
---|
gossypol beta-aminoethyl sodium sulfate |
megasin |
gossypol baes |
(2,2'-binaphthalene)-1,1',6,6',7,7'-hexol, 3,3'-dimethyl-5,5'-bis(1-methylethyl)-8,8'-bis(((2-(sulfooxy)ethyl)imino)methyl)-, disodium salt |
76500-07-7 |
disodium;2-[[2,3,8-trihydroxy-6-methyl-4-propan-2-yl-7-[1,6,7-trihydroxy-3-methyl-5-propan-2-yl-8-(2-sulfonatooxyethyliminomethyl)naphthalen-2-yl]naphthalen-1-yl]methylideneamino]ethyl sulfate |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" The effectiveness of the inducers increased markedly when used in combination with the specific vaccine against HAEM virus." | ( [Comparative study of the effectiveness of the interferon inducers, poly(I) : poly(C) and GSS (gossypol-beta-aminoethylsodium sulfate), in combination with a specific vaccine in experimental infection with the human acute encephalomyelitis virus]. Barinskiĭ, IF; Dushanbieva, S; Vagabov, RM, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (1)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |